Takeda

For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation. Today, our organization spans the globe—colleagues across business units and functions face challenges head-on to deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.

As a values-based, R&D-driven biopharmaceutical leader headquartered in Japan, we focus our R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. In addition to our R&D efforts, we’re laser-focused on harnessing the power of data, digital, and technology to improve health outcomes for patients across the globe.

Since our founding in Japan, integrity and putting patients first have been at the heart of our identity. We’re proud of our employees and their commitment to improving the quality of life for patients, and to working with our partners in health care in approximately 80 countries and regions. With each new breakthrough comes opportunities to develop your career, hone new skills, and create a brighter future.

For more information, visit https://jobs.takeda.com/

650 East Kendall Street Cambridge MA 02421 US
  • Featured Employer Badge
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • Takeda Top Global Employer 2024
  • Takeda LinkedIn Top 2024.png
  • 2025BPTW_GeneralBadge_FullColor.png
  • Takeda Disability Equality 2024
  • Takeda BGH 2024.png
CULTURE

At Takeda, we share a vision for the future where health care is more accessible, inclusive, sustainable, and affordable for all. And we believe our people are our greatest promise for delivering it. Individually, from R&D to IT, Finance to Maintenance, and every department in between, each of us brings the expertise, dedication, passion, and courage it takes to make history every day and change health care forever.

We’re grounded in over 240 years of history and are inspired each and every day by the possibility our future holds. Since our founding in Japan in 1781, integrity and putting patients first have been at the heart of our identity. These principles are ingrained in our culture and inspire our vision for the future. Our founding values remain core to our culture today and will inspire ideas that help you create a better tomorrow.

Across all parts of the business and corners of the world, our values unite and guide us. Our values are more than words on a page. They guide everything we do, uniting our teams across the world and lead us into the future. Our teams span the globe and work across a broad range of therapeutic areas, but we are connected by a shared values system. Bring your collaborative mindset and commitment and help us deliver the vision.

We’re dedicated to patients, our people, and the planet and proud of the contributions made by all our employees to drive impact. Each person’s contributions help us do better for patients, our fellow colleagues, and the planet. Take pride in knowing you help create a brighter future for patients, people, and the planet.

We’re constantly evolving—acting with endurance in our steadfast pursuit to achieve the best outcomes for our patients. We’re future-focused, delivering life-changing treatments through innovation. The drive to do better for patients means we are continuously evolving as a company and within our individual roles. Pursue new possibilities for patients while discovering new opportunities to grow your career.

DIVERSITY, EQUITY & INCLUSION

Across Takeda, we embrace and celebrate diversity, while striving to give patients and our people equitable access to opportunities that help them achieve their full potential. We take a values-based approach to inclusive patient experiences, inclusive work environments, workforce diversity and sustainable societal impact. We believe that diverse perspectives and experiences are key drivers of innovation. This starts with fostering an environment that creates a sense of belonging, allowing not only for everyone to have a voice, but a voice that is heard and valued.

NEWS
Takeda will advance its experimental drug for plaque psoriasis, TAK-279, to Phase III later this year after the TYK2 inhibitor met its primary and secondary endpoints in a Phase IIb study.
In spite of a tumultuous economy, many life science companies have started the year off strong. With plans to expand its team and pipeline in the coming year, Takeda is one of them.
Takeda’s vedolizumab met its primary endpoint in the Phase III GRAPHITE study, significantly improving event-free survival in patients with acute graft-versus-host disease.
Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.
Takeda and Arrowhead Pharmaceuticals’ Phase II trial studying fazirsiran, an investigational RNA therapeutic developed for AATD-LD, was effective in Phase II–but so was the placebo.
On the heels of positive Phase IIb data in plaque psoriasis, Takeda is acquiring both the therapy and Nimbus Lakshmi, a wholly owned subsidiary, in a potentially $6 billion deal.
The FDA granted priority review to Takeda’s Biologics License Application for TAK-003, a dengue vaccine candidate. The vaccine to date is only approved for use in Indonesia.
The HHS Office of Inspector General found that of 278 accelerated approvals between 1992 and 2021, 104 had incomplete confirmatory trials, according to a report issued Thursday.
Celltrion agreed Wednesday to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could net as much as $1.75 billion. See inside for more cancer collaborations.
JOBS
IN THE PRESS